### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Single Technology Appraisal**

## Sipavibart for preventing COVID-19 [ID6282]

### Final Stakeholder list

	submit or appeal)
	сиини ст иррош,
Company	General
AstraZeneca (sipavibart)	All Wales Therapeutics and Toxicology
	Centre
Patient/carer groups	Allied Health Professionals Federation
Action for Pulmonary Fibrosis	Board of Community Health Councils in
African Caribbean Leukaemia Trust	Wales
Anthony Nolan	British National Formulary
Aplastic Anaemia Trust	Care Quality Commission
Blood Cancer UK	Chest, Heart and Stroke Scotland
Cancer52	Department of Health, Social Services
Cardiomyopathy UK	and Public Safety for Northern Ireland
Cardiothoracic Transplant Patient	Diabetes UK Cymru
Group	Healthcare Improvement Scotland
Chronic Lymphocytic Leukaemia	Hospital Information Services -
Support Association	Jehovah's Witnesses
Chronic Myeloid Leukaemia Support	Long Covid Scotland
Group	Medicines and Healthcare products  Description: A new part
<ul><li>Clinically Vulnerable Families</li><li>Crohn's &amp; Colitis UK</li></ul>	Regulatory Agency
	National Association of Primary Care     National Pharmacy Association
<ul><li>Diabetes UK</li><li>DKMS</li></ul>	<ul><li>National Pharmacy Association</li><li>NHS Alliance</li></ul>
	NII 10 0 1 1 1
<ul><li>Down's Syndrome Association</li><li>Forgotten Lives UK</li></ul>	<ul> <li>NHS Confederation</li> <li>Northern Ireland Chest, Heart and</li> </ul>
<ul><li>Forgotten Lives UK</li><li>Immunodeficiency UK</li></ul>	Stroke Association
Kidney Care UK	Scottish Medicines Consortium
Kidney Research UK	Welsh Government
Leukaemia Cancer Society	Welsh Health Specialised Services
Leukaemia Caricel Society     Leukaemia Care	Committee
Leukaemia UK	Committee
Long Covid Kids	Comparator companies
Long Covid Physio	None
Long COVID SOS	
Long Covid Support	Relevant research groups
Lupus UK	Cochrane Infections Diseases Group
Lymphoma Action	Cochrane UK
Macmillan Cancer Support	Genomics England
MDS UK Patient Support Group	Institute of Cancer Research
Metabolic Support UK	Leukaemia Busters

Final Stakeholder list for the Single Technology Appraisal of sipavibart for preventing COVID-19 [ID6282] Issue date: August 2024

Appendix C

## **Provisional Consultees Provisional Commentators (no right to** submit or appeal) Long Covid Research Initiative MS Society Multiple Sclerosis Trust MRC Clinical Trials Unit Myeloma UK Associated Public Health groups National Kidney Federation **Public Health Wales** National Rheumatoid Arthritis Society **UK Health Security Agency** Polycystic Kidney Disease Charity Sarcoidosis UK Scleroderma and Raynaud's UK South Asian Health Foundation Specialised Healthcare Alliance Vasculitis UK Professional groups Association for Clinical Biochemistry and Laboratory Medicine Association of British Neurologists **Association of Cancer Physicians British Geriatrics Society British HIV Association British Infection Association** British Paediatric Allergy Infection and **Immunity Group** British Society for Allergy and Clinical **Immunology** British Society for Haematology British Society for Heart Failure British Society for Immunology British Society for Rheumatology British Society of Blood and Marrow Transplantation and Cellular **Therapies British Thoracic Society British Transplant Society** Cancer Research UK Faculty of Pharmaceutical Medicine Infection Prevention Society Microbiology Society NHS Blood and Transplant Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine **UK Clinical Pharmacy Association UK CLL Forum**

Appendix C

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul> <li>UK Kidney Association</li> <li>UK Renal Pharmacy Group</li> <li>Others</li> <li>Department of Health and Social Care</li> <li>NHS England</li> <li>NHS North East and North Cumbria ICB</li> <li>NHS South East London ICB</li> </ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts, and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### **Commentators**

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National

Final Stakeholder list for the Single Technology Appraisal of sipavibart for preventing COVID-19 [ID6282] Issue date: August 2024

<sup>&</sup>lt;sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.

Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.